Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM.CD40L Vaccine with Cyclophosphamide and ATRA in Lung Cancer
NCT00601796Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2006
- Primary completion
- Jun 2012
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GM.CD40L in lung adenocarcinoma, sponsored by Moffitt Cancer Center. Primary endpoint: Number of Evaluable Participants With Tumor Response at 3 years. Started Oct 2006; status: completed.
02
Drugs
GM.CD40L
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT00601796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00601796.